Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors

Journal of Nuclear Medicine

Volumn 38, Issue 7, 1997, Pages 1003-1008

  Kostakoglu, Lale ^a   Elahi, Nazenin ^a   Kïratlï, Pïnar ^a   Ruacan, Şevket ^a   Sayek, Iskender ^a   Baltalï, Eşmen ^a   Sungur, Arzu ^a   Hayran, Mutlu ^a   Bekdik, Coşkun F ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Multidrug resistance; P glycoprotein; Technetium 99m sestamibi

Indexed keywords

TECHNETIUM 99M;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; HUMAN; LUNG CANCER; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, MEDULLARY; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI;

EID: 0030856494     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987;84:265-269.
2. Gros P, Talbot F, Tang-Wai D, Bibi E, Kaback HR. Lipophilic cations: a group of model substrates for the multidrug-resistance transporter. Biochemistry 1992;31:1992-1998.
3. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant p-glycoprotein with an organotechnetium complex. Cancer Res 1993;53:977-984.
4. Rao VV, Chiu ML, Kronauge JF, Piwnica-Worms D. Expression of recombinant human multidrug resistance p-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi. J Nucl Med 1994;35:510-515.
5. Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. J Nucl Med 1990;31:1646-1653.
6. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 1990;82:1826-1838.
7. Goldstein LJ, Gaski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989;81:116-124.
8. Ross DD, Thompson BW, Ordonez JV, Joneckis CC. Improvement of flow-cytometric detection of multidrug-resistant cells by cell-volume normalization of intracellular daunorubicin content. Cytometty 1989;10:185-191.
9. Lampidis TJ, Castello C, del Giglio A, et al. Relevance of chemical charge of rhodamine dyes to multiple-drug resistance. Biochem Pharmacol 1989;38:4267-4271.
10. Chan H, Thorner P, Haddad G, Ling V. Immunohistochemical detection of p-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990;8:689-704.
11. Kessel D, Beck WT, Kukuruga D, Schulz V. Characterization of multidrug resistance by fluorescent dyes. Cancer Res 1991;51:4665-4670.
12. Noonan KE, Beck WT, Holzmayer TA, et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci 1990;87:7160-7164.
13. Sternberger LA. Immunocytochemistry, 3rd ed. New York: Wiley; 1986.
14. 99mTc-sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology 1995;196:421-426.
15. Abdel-Dayem HM, Scott AM, Macapinlac HA, et al. In: Freeman LM, ed. Nuclear medicine annual. New York: Raven Press; 1994:181-234.
16. Duran Cordobes M, Starzes A, Delmon-Moingeon L, et al. Technetium-99m uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression. J Nucl Med 1996;37:286-289.
17. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression of p-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995;333:1380-1385.
18. Ludescher C, Hilbe W, Eisterer W, et al. Activity of p-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay. J Natl Cancer Inst 1993;85:1751-1758.
19. Cardon Cardo C, O'Brien JB, Boccia J, et al. Expression of multidrug-resistance gene product (p-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990;38:1277-1287.
20. Charpin C, Vielh P, Duffaud F, et al. Quantitative immunocytochemical assays of p-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J Natl Cancer Inst 1994;86:1539-1545.
21. Lai SL, Goldstein LJ, Gottesman MM, et al. MDR1 gene expression in lung cancer. J Natl Cancer Inst 1989;81:1144-1150.
22. Twentyman PR. MDR1 (p-glycoprotein) gene expression-implications for resistance modifier trials [Editorial]. J Natl Cancer Inst 1992;84:1458-1460.